<DOC>
	<DOCNO>NCT00217269</DOCNO>
	<brief_summary>The purpose study assess equivalence safety efficacy Endeavor Drug Eluting Coronary Stent System compare Taxus Paclitaxel-Eluting Coronary Stent System treatment single de novo lesion native coronary artery reference vessel diameter ( RVD ) 2.5-3.5 mm .</brief_summary>
	<brief_title>The ENDEAVOR IV Clinical Trial : A Trial Coronary Stent System Coronary Artery Lesions</brief_title>
	<detailed_description>The ENDEAVOR IV Trial prospective , multi-center , randomize , two-arm , single-blind trial enroll total 1,548 patient 80 site US . The ENDEAVOR IV Trial ass Endeavor stent equivalent safety efficacy Taxus stent treatment single de novo lesion native coronary artery RVD 2.5-3.5 mm .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>The patient clinical evidence ischemic heart disease , stable unstable angina , silent ischemia , positive functional study . The patient acceptable candidate percutaneous transluminal coronary angioplasty ( PTCA ) , stenting , emergent coronary artery bypass graft ( CABG ) surgery . Female patient childbearing potential must negative pregnancy test within 7 day procedure . The patient patient 's legal representative inform nature study agree provision provide write informed consent approve Institutional Review Board/Ethics Committee ( IRB/EC ) respective clinical site . The patient agree return research facility require postprocedure followup visit . A known hypersensitivity contraindication aspirin , heparin bivalirudin , ticlopidine clopidogrel , cobalt , nickel , chromium , molybdenum , polymer coating ( e.g. , Phosphorylcholine Translute ) , sensitivity contrast medium , adequately premedicated . History allergic reaction significant sensitivity drug ABT578 , rapamycin , tacrolimus , everolimus , analogue derivative . History allergic reaction significant sensitivity paclitaxel drug similar class . A platelet count &lt; 100,000 cells/mm³ &gt; 700,000 cells/mm³ , white blood cell ( WBC ) count &lt; 3,000 cells/mm³ . A serum creatinine level &gt; 2.0 mg/dl within seven day prior index procedure . Evidence acute MI within 72 hour intend index procedure ( define : QWMI nonQ wave myocardial infarction ( NQWMI ) CK enzymes &gt; 2X upper laboratory normal presence CKMB elevate Institution 's upper limit normal ) . Previous PCI target vessel within 9 month preprocedure . Planned PCI vessel within 30 day postprocedure . During index procedure , target lesion require treatment device PTCA prior stent placement ( include limit , cut balloon , atherectomy , laser , thrombectomy , etc. ) . History stroke transient ischemic attack ( TIA ) within prior 6 month . Active peptic ulcer upper gastrointestinal ( GI ) bleeding within prior 6 month . History bleed diathesis coagulopathy refuse blood transfusion . Concurrent medical condition life expectancy le 12 month . Any previous plan treatment target vessel antirestenotic therapy include , limited brachytherapy . Currently participate investigational drug another device study complete primary endpoint clinically interfere current study endpoint ; require coronary angiography , IVUS coronary artery imaging procedure . Documented leave ventricular ejection fraction ( LVEF ) &lt; 30 % recent evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Restenosis</keyword>
</DOC>